Article
S-Equol mitigates motivational deficits and dysregulation associated with HIV-1.
Scientific reports - 4 Jun 2021
McLaurin Kristen A, Bertrand Sarah J, Illenberger Jessica M, Harrod Steven B, Mactutus Charles F, Booze Rosemarie M
Abstract excerpt
Motivational deficits (e.g., apathy) and dysregulation (e.g., addiction) in HIV-1 seropositive individuals, despite treatment with combination antiretroviral therapy, necessitates the development of innovative adjunctive therapeutics. S-Equol (SE), a selective estrogen receptor β agonist, has been implicated as a neuroprotective and/or neurorestorative therapeutic for HIV-1 associated neurocognitive disorders...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
